Self-Assembling Peptide Amphiphile-Based Nanofiber Gel for Bioresponsive Cisplatin Delivery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jin-Ki | - |
dc.contributor.author | Anderson, Joel | - |
dc.contributor.author | Jun, Ho-Wook | - |
dc.contributor.author | Repka, Michael A. | - |
dc.contributor.author | Jo, Seongbong | - |
dc.date.accessioned | 2021-06-23T15:39:27Z | - |
dc.date.available | 2021-06-23T15:39:27Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2009-05 | - |
dc.identifier.issn | 1543-8384 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/41263 | - |
dc.description.abstract | The aim of this study is to develop a bioresponsive cisplatin (CDDP) delivery system with a self-assembling peptide amphiphile (PA) comprising a cell-adhesive matrix metalloproteinase-2 (MMP-2)-sensitive GTAGLIGQRGDS and a fatty acid. A biomimetic CDDP-PA gel was spontaneously formed upon incubating a mixture of CDDP and the PA for 5 h at 37 degrees C. CDDP-PA gel formation was confirmed by rheological analysis. The structure of self-assembled CDDP-PA nanofibers inside the gel was determined by transmission electron microscopy (TEM). Bioresponsive drug release from the biomimetic gel was demonstrated by in vitro MMP-2-triggered CDDP release. The MMP-2-sensitive CDDP release was dependent on the enzyme concentration in the medium. Enzymatic degradation of the CDDP-PA gel was confirmed by TEM images of the gel degraded in an MMP-2 containing medium. The MMP-2-triggered CDDP release as well as the presentation of RGDS in the gel would potentially provide a spatially and temporally controlled delivery system for targeted anticancer drug delivery. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Self-Assembling Peptide Amphiphile-Based Nanofiber Gel for Bioresponsive Cisplatin Delivery | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jin-Ki | - |
dc.identifier.doi | 10.1021/mp900009n | - |
dc.identifier.scopusid | 2-s2.0-67249114390 | - |
dc.identifier.wosid | 000266652600033 | - |
dc.identifier.bibliographicCitation | MOLECULAR PHARMACEUTICS, v.6, no.3, pp.978 - 985 | - |
dc.relation.isPartOf | MOLECULAR PHARMACEUTICS | - |
dc.citation.title | MOLECULAR PHARMACEUTICS | - |
dc.citation.volume | 6 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 978 | - |
dc.citation.endPage | 985 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MESENCHYMAL STEM-CELLS | - |
dc.subject.keywordPlus | HYBRID SCAFFOLD | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordPlus | THERAPEUTICS | - |
dc.subject.keywordPlus | STRATEGIES | - |
dc.subject.keywordPlus | COMPLEX | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | matrix metalloproteinase-2 | - |
dc.subject.keywordAuthor | nanofiber | - |
dc.subject.keywordAuthor | peptide amphiphile | - |
dc.subject.keywordAuthor | targeted drug delivery | - |
dc.identifier.url | https://pubs.acs.org/doi/10.1021/mp900009n | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.